← Search & browse all drugs
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES › Other agents against amoebiasis and other protozoal diseases
chiniofon
P01AX01
Forms & Strengths
- Oral tablets: 250 mg
- Oral tablets: 500 mg
- Oral suspension: 125 mg/5 mL
Adult Dosing
- Entamoebiasis: 500 mg PO q8h for 5–7 days
- Giardiasis: 500 mg PO q12h for 5 days
- Severe infection: 500 mg PO q6h, max 3 g/day
Pediatric Dosing
- Children 2–12 yr: 15–20 mg/kg/day PO divided q8h (max 500 mg per dose)
- Infants <2 yr: 10–15 mg/kg/day PO divided q8h
- Duration: 5–7 days depending on indication
Indications
- Amoebic dysentery (Entamoeba histolytica)
- Giardiasis (Giardia lamblia)
- Intestinal protozoal infections resistant to metronidazole
Mechanism of Action
- Inhibits protozoal pyruvate:ferredoxin oxidoreductase, disrupting energy metabolism
- Interferes with nucleic acid synthesis in susceptible parasites
Contraindications
- Known hypersensitivity to chiniofon or related nitro‑heterocycles
- Severe hepatic impairment
- Pregnancy (Category D) unless benefits outweigh risks
- Lactation (risk to infant)
Adverse Reactions
- Gastrointestinal upset: nausea, vomiting, abdominal cramps
- Transient elevation of liver transaminases
- Rash or pruritus
- Rare neutropenia or thrombocytopenia
- Metallic taste
Drug Interactions
- Warfarin: may potentiate anticoagulant effect → monitor INR
- Oral contraceptives: possible reduction in efficacy → advise backup method
- Metronidazole: additive GI toxicity; avoid concurrent high‑dose regimens
- Cimetidine: may increase plasma levels of chiniofon
Curated Content: Needs Vetting Before Put to Clinical Use